Nu Skin Enterprises, Inc.
NUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.47 | -0.06 | -0.00 | 0.00 |
| FCF Yield | 2.92% | 9.06% | -3.65% | 3.85% |
| EV / EBITDA | 29.66 | 10.27 | 3.01 | -17.86 |
| Quality | ||||
| ROIC | 1.94% | 1.98% | -0.69% | -2.72% |
| Gross Margin | 70.49% | 68.82% | 67.76% | 62.65% |
| Cash Conversion Ratio | 1.61 | 1.69 | 0.00 | -0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.98% | -7.30% | -7.21% | -8.02% |
| Free Cash Flow Growth | -50.90% | 371.14% | -199.95% | -42.19% |
| Safety | ||||
| Net Debt / EBITDA | 1.83 | 1.08 | 0.64 | -8.21 |
| Interest Coverage | 5.22 | 12.19 | -3.02 | -9.05 |
| Efficiency | ||||
| Inventory Turnover | 0.60 | 0.67 | 0.62 | 0.87 |
| Cash Conversion Cycle | 137.69 | 127.27 | 132.81 | 94.29 |